Brief: UK's MHRA Approves Mirdametinib To Treat Plexiform Neurofibromas
11/12/2025 14:34
Dec 11 (Reuters) - UK's MHRA: UK'S MHRA: MIRDAMETINIB APPROVED TO TREAT PLEXIFORM NEUROFIBROMAS IN CHILDREN, ADOLESCENTS, AND ADULTS WITH NEUROFIBROMATOSIS TYPE 1 - WEBSITE Further company coverage: MRCG.DE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck KGaA
See all newsUS stocks weekly: AI reality
US stocks weekly: AI reality
Brief: Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain Circumstances - SEC Filing
Press Digest: Financial Times - June 26
US STOCKS-Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook